• 1. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 4. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 5. Alternative mixtures to R-600a. Theoretical assessment and experimental energy evaluation of binary mixtures in a commercial cooler: Mélanges alternatifs au R-600a. évaluation théorique et évaluation énergétique expérimentale de mélanges binaires dans un refroidisseur commercial.
  DanielCalleja-Anta,DanielSánchez,LauraNebot-Andres,RamónCabello,RodrigoLlopis

Introduction to Streptomycin Hydrochloride (CAS No 6160-32-3)

Streptomycin hydrochloride, with the chemical formula C₂₁H₃₉N₇O₁₂HCl, is a well-established antibiotic that has played a pivotal role in the treatment of various bacterial infections since its discovery in the 1940s. This compound, derived from the soil bacterium *Streptomyces griseus*, belongs to the aminoglycoside class of antibiotics and is widely recognized for its efficacy against Gram-negative bacteria. The CAS No 6160-32-3 identifier uniquely classifies this substance, ensuring precise identification and regulatory compliance in pharmaceutical and research settings.

The mechanism of action for streptomycin hydrochloride involves inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, thereby disrupting the translation process. This interference leads to the production of faulty proteins, ultimately causing bacterial cell death. Its effectiveness against a broad spectrum of pathogens has made it a cornerstone in the treatment of tuberculosis (TB) and other serious infections. However, the rise of antibiotic-resistant strains has prompted ongoing research into optimizing its use and developing novel derivatives.

In recent years, advancements in biotechnology have enabled the large-scale production of streptomycin hydrochloride, making it more accessible for therapeutic applications. Modern fermentation techniques and purification methods have significantly improved yield and purity, ensuring higher efficacy and reduced side effects. Additionally, research into combination therapies involving streptomycin hydrochloride with other antibiotics has shown promise in combating multidrug-resistant bacteria, highlighting its enduring relevance in modern medicine.

The chemical structure of streptomycin hydrochloride consists of an aminocyclitol ring system linked to various amino sugars, which contributes to its complex biological activity. The hydrochloride salt form enhances solubility and stability, making it more suitable for intravenous and oral administration. This formulation has been critical in ensuring consistent drug delivery and therapeutic outcomes for patients worldwide.

Current research endeavors are focused on overcoming limitations associated with streptomycin hydrochloride, such as ototoxicity and nephrotoxicity. Novel derivatives are being investigated to mitigate these adverse effects while preserving antimicrobial potency. For instance, modifications to the aminocyclitol core have yielded compounds with improved pharmacokinetic profiles, offering new avenues for treating resistant bacterial infections.

The global impact of streptomycin hydrochloride extends beyond clinical applications; it has also been instrumental in public health initiatives aimed at controlling TB outbreaks. Its affordability and availability have made it a preferred choice in resource-limited settings, where access to advanced medical treatments is often constrained. Collaborative efforts between academia, industry, and healthcare organizations continue to drive innovation in streptomycin hydrochloride-based therapies.

In conclusion, streptomycin hydrochloride(CAS No 6160-32-3) remains a vital component of antimicrobial therapy despite challenges posed by antibiotic resistance. Ongoing research into its mechanisms of action, structural modifications, and combination therapies underscores its enduring significance in addressing global health challenges. As scientific understanding evolves, so too will strategies for maximizing the benefits of this remarkable compound while minimizing its risks.

• 128-46-1(N-(1R,2R,3S,4R,5R,6S)-3-carbamimidamido-4-{(2R,3R,4R,5S)-3-{(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yloxy}-4-hydroxy-4-(hydroxymethyl)-5-methyloxolan-2-yloxy}-2,5,6-trihydroxycyclohexylguanidine)
• 26086-49-7(Desoxymycin)
• 123482-11-1(D-Streptamine,O-2-C-carboxypentofuranosyl-(1®4)-O-2-deoxy-2-(methylamino)-a-L-glucopyranosyl-(1®2)-O-5-deoxy-3-C-formyl-a-L-lyxofuranosyl-(1®4)-N,N'-bis(aminoiminomethyl)- (9CI))
• 100759-54-4(D-Streptamine, O-a-D-mannopyranosyl-(1®6)-O-b-D-mannopyranosyl-(1®4)-O-2-deoxy-2-(methylamino)-a-L-glucopyranosyl-(1®2)-O-5-deoxy-3-C-formyl-a-L-lyxofuranosyl-(1®4)-N,N'-bis(aminoiminomethyl)-(9CI))
• 15493-35-3(Streptomycin calcium chloride)
• 3810-74-0(Streptomycin sulfate)
• 28979-71-7(4-O-[2-O-[4-O-β-D-Mannopyranosyl-2-(methylamino)-2-deoxy-α-L-glucopyranosyl]-3-formyl-α-L-lyxofuranosyl]-N,N'-bis(aminoiminomethyl)-D-streptamine)
• 123482-12-2(D-Streptamine,O-2-deoxy-2-[(hydroxyacetyl)methylamino]-a-L-glucopyranosyl-(1®2)-O-5-deoxy-3-C-formyl-a-L-lyxofuranosyl-(1®4)-N,N'-bis(aminoiminomethyl)- (9CI))
• 128-45-0(D-Streptamine, O-b-D-mannopyranosyl-(1®4)-O-2-deoxy-2-(methylamino)-a-L-glucopyranosyl-(1®2)-O-5-deoxy-3-C-formyl-a-L-lyxofuranosyl-(1®4)-N1,N3-bis(aminoiminomethyl)-)
• 29047-73-2(Mannosidodihydrostreptomycin)